Beyond Batten Disease Foundation

THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)

Alejandra Tijerina — Fri, 04 Sep 2026 19:25:13 +0000

Lyon, France – Austin, Texas, USA – Gentilly, France – September 1st, 2026 – [TIME] CET – THX Pharma (Theranexus), an innovative biopharmaceutical company developing treatments for rare neurological diseases, together with its partners, the Beyond Batten Disease Foundation (BBDF) and Biocodex, today announced the submission of regulatory applications to initiate the Phase 3 clinical […]

The post THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3) appeared first on Beyond Batten Disease Foundation.

BBDF-Funded Clinical Recommendations Mark a Major Milestone for CLN3 Disease Care

Alejandra Tijerina — Thu, 16 Jul 2026 13:56:14 +0000

Beyond Batten Disease Foundation is proud to share a major milestone for families, clinicians, and researchers working to improve care for individuals affected by CLN3 juvenile Batten disease: the publication of the first comprehensive international guidelines for the diagnosis and management of CLN3 disease. Published in Orphanet Journal of Rare Diseases, the article provides an […]

The post BBDF-Funded Clinical Recommendations Mark a Major Milestone for CLN3 Disease Care appeared first on Beyond Batten Disease Foundation.

THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day

Alejandra Tijerina — Tue, 09 Jun 2026 20:49:27 +0000

Lyon, France – Gentilly, France – Austin, Texas, United States – June 9, 2026 – 8:00 am CEST – On the occasion of International Batten Disease Awareness Day happening today, THX Pharma (Theranexus), a biopharmaceutical company specializing in the development of innovative treatments for rare neurological diseases, Biocodex, an independent international pharmaceutical group and long-time […]

The post THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day appeared first on Beyond Batten Disease Foundation.

THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases.

Alejandra Tijerina — Wed, 25 Feb 2026 14:52:55 +0000

Lyon et Gentilly, France, 10 February 2026, 6.00 pm CET – THX Pharma (Theranexus), a biopharmaceutical company specializing in the treatment of rare neurological diseases, and Biocodex, an independent international pharmaceutical group, announce the execution of a strategic licensing agreement to advance the development of two drug candidates in three rare diseases with high unmet […]

The post THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases. appeared first on Beyond Batten Disease Foundation.

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases

Alejandra Tijerina — Mon, 29 Sep 2025 20:22:08 +0000

With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, early access, and international commercialization of its medicines. Lyon, France – September 29, 2025, 6 pm CEST – THX Pharma (formerly Theranexus), a pharmaceutical company specializing in rare neurological diseases, today unveils its new corporate and brand identity , […]

The post Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases appeared first on Beyond Batten Disease Foundation.

Theranexus and Beyond Batten Disease Foundation Announce Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of Batten Disease

Alejandra Tijerina — Wed, 14 May 2025 13:13:28 +0000

Lyon, France – Austin, Texas, United States – Mai 13, 2025 – 6.00 pm CET –Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases and the Beyond Batten Disease Foundation (BBDF), today announced new real-world data strongly supporting the efficacy of Batten-1 (miglustat) as a treatment for CLN3 disease, also known as juvenile […]

The post Theranexus and Beyond Batten Disease Foundation Announce Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of Batten Disease appeared first on Beyond Batten Disease Foundation.

Family Research Calls – May 13 & 15

Alejandra Tijerina — Wed, 30 Apr 2025 13:29:28 +0000

Dear BBDF Family Partners, Please join us on our next two family research calls. You will need to register for each call separately. Tuesday, May 13 at 3 p.m. CST – we will be sharing an update on the Batten-1 clinical trial. Please register to participate in the call here. Thursday, May 15 at 2 p.m. CST – we will […]

The post Family Research Calls – May 13 & 15 appeared first on Beyond Batten Disease Foundation.

Batten Disease Global Research Initiative Announces Inaugural Grant Recipients

Alejandra Tijerina — Thu, 10 Apr 2025 13:11:59 +0000

March 18, 2025 Batten Disease Global Research Initiative Announces Inaugural Grant Recipients The Batten Disease Global Research Initiative (BDGRI) is proud to announce the recipients of its inaugural Research Grant round, awarding a total of USD $320,000 to six groundbreaking projects worldwide. Following a robust selection process by a Grant Review Panel of eight international Batten disease […]

The post Batten Disease Global Research Initiative Announces Inaugural Grant Recipients appeared first on Beyond Batten Disease Foundation.

Batten-1 May Preserve Vision with Juvenile Batten Disease

Alejandra Tijerina — Tue, 03 Dec 2024 22:06:26 +0000

Findings in Phase 1/2 clinical trial, access program also support miglustat’s safety. by Margarida Maia, PhD | December 2, 2024 Batten Disease News

The post Batten-1 May Preserve Vision with Juvenile Batten Disease appeared first on Beyond Batten Disease Foundation.

Update on the Theranexus’ Batten-1 project in CLN3 Batten’s disease

Alejandra Tijerina — Wed, 20 Nov 2024 21:31:10 +0000

Lyon, France – Austin, Texas, United States – November 19, 2024 – 6 PM CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, and the Beyond Batten Disease Foundation (BBDF) presented the final and positive results of the Phase I/II trial to evaluate Batten-1 in 6 young adult patients with […]

The post Update on the Theranexus’ Batten-1 project in CLN3 Batten’s disease appeared first on Beyond Batten Disease Foundation.